List of Excipients in Branded Drug REZZAYO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Melinta Therapeutics LLC	REZZAYO	rezafungin	70842-240	HISTIDINE	2035-03-22
Melinta Therapeutics LLC	REZZAYO	rezafungin	70842-240	HYDROCHLORIC ACID	2035-03-22
Melinta Therapeutics LLC	REZZAYO	rezafungin	70842-240	MANNITOL	2035-03-22
Melinta Therapeutics LLC	REZZAYO	rezafungin	70842-240	POLYSORBATE 80	2035-03-22

Rezzayo Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Rezzayo (rezafungin for injection) is a once-weekly intravenous echinocandin approved by the FDA for adults with candidemia and invasive candidiasis when treatment options are limited or unavailable. Its commercial formulation is a 200 mg lyophilized vial containing rezafungin with sucrose, mannitol, and polysorbate 80. The principal excipient opportunities are formulation lifecycle management, ready-to-use delivery, container-closure optimization, infusion compatibility, and generic development rather than substitution of the core excipients alone. [1]

What excipients are used in Rezzayo?

The approved Rezzayo product is a sterile lyophilized powder for intravenous infusion. The FDA prescribing information identifies sucrose, mannitol, and polysorbate 80 as inactive ingredients. The product is reconstituted with Sterile Water for Injection and diluted before administration in either 0.9% sodium chloride injection or 5% dextrose injection. [1]

Product attribute	Rezzayo specification
Active ingredient	Rezafungin
Dosage form	Lyophilized powder for injection
Strength	200 mg per vial
Administration	Intravenous infusion
Loading dose	400 mg on Day 1
Maintenance dose	200 mg once weekly
Primary excipients	Sucrose, mannitol, polysorbate 80
Reconstitution	Sterile Water for Injection
Further dilution	0.9% sodium chloride or 5% dextrose
Indication	Candidemia and invasive candidiasis in adults with limited or no alternative treatment options
FDA approval	March 22, 2023
Regulatory sponsor	Cidara Therapeutics, with commercial rights arrangements involving Mundipharma

Sucrose is commonly used as a bulking and stabilizing agent in lyophilized biologic and small-molecule injectable products. Mannitol can provide cake structure and bulking capacity during freeze-drying. Polysorbate 80 reduces surface adsorption and aggregation risks associated with reconstitution, handling, and infusion.

The excipient combination is commercially conventional. The formulation value lies in the specific ratio, freeze-drying cycle, reconstitution behavior, stability profile, and container-closure system rather than in the individual ingredients.

How does the Rezzayo formulation work?

Rezzayo’s excipient system supports a stable lyophilized cake that can be reconstituted for intravenous administration. The formulation has four practical functions:

1. It protects rezafungin during freezing and drying.
2. It provides a physically acceptable lyophilized cake.
3. It permits reconstitution with Sterile Water for Injection.
4. It supports subsequent dilution into standard hospital infusion fluids.

Mannitol is often used to improve cake structure and reduce collapse during lyophilization. Sucrose can provide amorphous-phase stabilization. Polysorbate 80 addresses interfacial stress caused by vial handling, reconstitution, and transfer into infusion bags.

The formulation must balance several competing properties:

• Cake appearance and mechanical integrity
• Reconstitution time
• Particulate control
• Protein-like aggregation or colloidal instability, despite rezafungin being a small-molecule cyclic lipopeptide
• Compatibility with infusion bags and tubing
• Stability after dilution
• Low extractables and leachables
• Tolerability during intravenous infusion

Because Rezzayo is administered weekly, a formulation defect that causes preparation delays or infusion failures can affect an entire treatment cycle. Hospital pharmacy workflow is therefore part of the commercial value proposition.

What formulation patents protect Rezzayo?

The relevant intellectual-property estate is likely to include composition-of-matter, formulation, manufacturing, and method-of-use rights. The highest-value claims generally relate to the rezafungin molecule and its use against invasive fungal infections. Excipient claims may protect a narrower formulation or process but do not necessarily control all future formulations containing rezafungin.

IP category	Commercial relevance	Typical claim scope
Composition of matter	Highest	Rezafungin chemical structure and salts or derivatives
Pharmaceutical composition	High	Rezafungin with defined excipient systems and concentration ranges
Lyophilization process	Medium to high	Freezing, drying, cycle parameters, cake quality, residual moisture
Reconstitution and dilution	Medium	Specified diluents, concentrations, stability periods
Method of use	High	Treatment of candidemia, invasive candidiasis, or fungal infections
Container closure	Medium	Vial, stopper, seal, and compatibility requirements
Manufacturing process	Medium	Purification, crystallization, impurity control, and scale-up

The Rezzayo label does not by itself establish the complete patent estate. Orange Book-listed patents, patent-term adjustments, pediatric exclusivity, and litigation history require review of the current FDA Orange Book and USPTO records. [2] A formulation competitor should not assume that designing around sucrose, mannitol, or polysorbate 80 avoids active-ingredient or method-of-use barriers.

When does Rezzayo lose exclusivity?

Rezzayo entered the U.S. market after FDA approval in 2023. FDA approval provides five years of new chemical entity exclusivity unless another statutory exclusivity period or patent right changes the practical market-entry date. That exclusivity generally prevents submission of an ANDA relying on the reference product for five years, subject to applicable statutory exceptions. [3]

The commercial entry date will depend on:

• Orange Book patent listings
• Patent expiration dates
• Patent-term adjustment
• Any pediatric exclusivity
• Paragraph IV challenges
• Litigation outcomes
• Settlement agreements
• Whether a generic applicant pursues a 505(b)(2) route instead of an ANDA

A practical exclusivity model should separate regulatory exclusivity from patent exclusivity.

Exclusivity layer	Rezzayo impact
New chemical entity exclusivity	Restricts ANDA submission during the statutory period
Listed drug patents	Can delay or litigate generic approval
Method-of-use patents	May require a skinny label or carve-out
Formulation patents	Can constrain a generic using the same formulation
Manufacturing patents	May affect API or drug-product sourcing
Pediatric exclusivity	Could add six months if awarded
Orphan exclusivity	Depends on the approved indication and orphan designation status

What Paragraph IV challenges could affect Rezzayo?

A Paragraph IV applicant could challenge listed patents by asserting that they are invalid, unenforceable, or not infringed. For Rezzayo, the most commercially relevant challenges would likely target:

• Broad rezafungin composition claims
• Formulation claims covering the lyophilized product
• Reconstitution or dilution claims
• Method-of-use claims for candidemia and invasive candidiasis
• Manufacturing claims that constrain API supply

A generic developer could also use a section viii statement to omit a patented method of use if the product label contains separable, non-patented indications. That approach is less useful when the principal commercial indication is closely tied to the listed method claims.

The risk profile depends on whether a generic can use the same inactive ingredients while changing concentration, lyophilization conditions, vial fill, or reconstitution instructions. A formulation change may avoid one patent while creating new FDA comparability and stability work.

What excipient strategies could create commercial opportunities?

Ready-to-use or pharmacy-ready presentations

The current lyophilized vial requires reconstitution and dilution. A premixed infusion bag, dual-chamber container, or pharmacy-ready presentation could reduce preparation time and manipulation risk.

Potential advantages include:

• Fewer aseptic transfers
• Lower pharmacy labor
• Reduced dosing errors
• Easier use in outpatient infusion centers
• Better support for weekly administration
• More predictable infusion preparation

The main technical barriers are solution stability, adsorption, particulate formation, container compatibility, and shelf life. A ready-to-use product could require a new drug application, a supplemental approval, or a 505(b)(2) pathway depending on the formulation and regulatory strategy.

Alternative stabilizer systems

Potential lifecycle approaches include evaluating trehalose, alternative polyols, amino acids, or surfactant combinations. Any replacement must preserve:

• Chemical stability
• Reconstitution time
• Infusion tolerability
• Cake structure
• Dilution compatibility
• Low particulate burden

An alternative excipient system is more valuable if it delivers a measurable advantage, such as room-temperature stability, a longer in-use period, reduced reconstitution time, or reduced sensitivity to agitation.

Surfactant optimization

Polysorbate 80 is widely used but can present oxidation, hydrolysis, peroxide, and particulate-control challenges. A lifecycle program could assess polysorbate 20, poloxamers, or other surfactant systems. The commercial case depends on whether the substitute improves stability or reduces supply-chain risk without increasing infusion reactions or analytical burden.

Container-closure improvements

A low-extractables vial and stopper system could support long-term stability and simplify global registration. Opportunities include:

• Low-peroxide elastomers
• Reduced tungsten or glass-related particulate exposure
• Improved stopper puncture performance
• Better protection against moisture
• Larger vial presentations for the 400 mg loading dose

The 400 mg loading dose requires two 200 mg vials under the current presentation. A 400 mg vial could reduce handling, packaging, and disposal costs, although it would require separate stability, manufacturing, and regulatory work.

Hospital-use packaging

A pharmacy package containing two 200 mg vials, transfer devices, compatible diluent, and preparation instructions could improve use of the loading dose. This would not necessarily change the drug product but could create a commercial packaging opportunity for hospitals and specialty distributors.

How strong is the excipient patent opportunity for Rezzayo?

The excipient patent opportunity is moderate rather than dominant. Sucrose, mannitol, and polysorbate 80 are established excipients with extensive prior art. A patent directed only to their presence in a rezafungin vial may face novelty and obviousness challenges.

Stronger claims would likely require a specific technical result, such as:

• A defined excipient ratio that improves rezafungin stability
• A lyophilization cycle that produces a stable cake with a specified residual-moisture range
• A reconstituted solution with extended room-temperature stability
• Reduced particulates after agitation or transport
• Improved compatibility with a specified infusion container
• A particular impurity profile after long-term storage

The best commercial strategy is to combine formulation claims with process and presentation claims. A competitor that avoids one claim category may still encounter barriers in another.

What generic entry risks exist for Rezzayo?

Generic entry could take several forms:

Conventional ANDA

A generic applicant could seek approval using an equivalent injectable dosage form and demonstrate pharmaceutical equivalence, bioequivalence where applicable, and manufacturing quality. The primary barriers would be listed patents, sterile manufacturing, formulation similarity, and stability.

505(b)(2) product

A modified product could use a different excipient system, different vial strength, ready-to-use bag, or alternative administration presentation. This route may offer differentiation but can attract patent litigation and require additional clinical or bridging data.

Hospital-compounded preparation

Compounding is not a direct substitute for FDA-approved generic supply. It may become relevant during shortages or in specialized settings but has limitations involving sterility, quality control, stability, and reimbursement.

The strongest near-term generic defense is likely to come from the active-ingredient patent estate and manufacturing complexity, not from the commodity status of the excipients.

What is the FDA regulatory status of Rezzayo?

The FDA approved Rezzayo in March 2023 for adults with candidemia and invasive candidiasis when treatment options are limited or unavailable. The product is administered once weekly after a loading dose, a dosing schedule that differentiates it from daily echinocandins such as anidulafungin, micafungin, and caspofungin. [1,4]

The regulatory profile supports several commercial positions:

• Inpatient treatment of invasive candidiasis
• Step-down or continuation therapy where weekly dosing has operational value
• Selected outpatient infusion settings
• Situations where daily echinocandin administration creates logistical burdens

Weekly intravenous administration does not eliminate the need for infusion-center infrastructure. The product still requires preparation, dilution, infusion monitoring, and management of hepatic or infusion-related safety considerations.

How does Rezzayo compare with competing echinocandins?

Product	Active ingredient	Typical dosing pattern	Formulation opportunity
Rezzayo	Rezafungin	Loading dose followed by weekly IV dosing	Ready-to-use presentation, 400 mg loading-dose package, stability
Eraxis	Anidulafungin	Daily IV dosing	Convenience disadvantage relative to weekly rezafungin
Mycamine	Micafungin	Daily IV dosing	Established generic and hospital procurement competition
Cancidas	Caspofungin	Daily IV dosing	Mature market and generic competition

Rezzayo’s commercial advantage is dosing frequency. Its formulation disadvantage is that it remains a lyophilized intravenous product requiring pharmacy preparation. Excipient innovation should therefore focus on preserving the weekly benefit while reducing preparation friction.

What licensing and partnership opportunities exist?

The most attractive licensing targets are:

• Ready-to-use rezafungin infusion technology
• Dual-chamber or closed-system reconstitution devices
• Low-peroxide surfactant platforms
• Lyophilization process technology
• Low-extractables container-closure systems
• Hospital pharmacy packaging
• Regional sterile manufacturing capacity

A deal could be structured around an exclusive formulation license, a co-development agreement, or a contract manufacturing arrangement. The strongest negotiating position would come from a technology that demonstrates a validated improvement in shelf life, preparation time, room-temperature handling, or outpatient usability.

Key Takeaways

• Rezzayo contains rezafungin with sucrose, mannitol, and polysorbate 80 in a 200 mg lyophilized vial.
• The main commercial opportunity is not replacing commodity excipients but improving stability, preparation, packaging, and administration.
• A 400 mg loading-dose presentation could reduce vial handling and pharmacy waste.
• Ready-to-use bags, dual-chamber containers, and closed-transfer systems have the clearest lifecycle value.
• Excipient patents are stronger when tied to a defined stability, lyophilization, particulate, or compatibility result.
• Generic entry will depend primarily on active-ingredient, formulation, method-of-use, and manufacturing patents.
• Rezzayo’s weekly dosing differentiates it from daily echinocandins, but the current IV preparation workflow limits the full convenience benefit.
• Supplier and licensing opportunities are strongest in sterile manufacturing, container closure, lyophilization, and hospital pharmacy systems.

FAQs

Can Rezzayo be reformulated as a premixed infusion?

Yes, but a premixed product would require demonstration of solution stability, container compatibility, sterility, particulate control, and acceptable in-use storage. The regulatory pathway would depend on the extent of the formulation change.

Would replacing polysorbate 80 create a generic product?

Not necessarily. A surfactant substitution may avoid a formulation claim, but the product could remain subject to composition-of-matter, method-of-use, manufacturing, or other listed patents.

Is a 400 mg Rezzayo vial commercially attractive?

Yes. It could support the Day 1 loading dose with one vial instead of two, reducing preparation steps, packaging, and waste. Its commercial value would depend on demand, stability, manufacturing cost, and patent coverage.

Are sucrose and mannitol strategic supply-chain risks?

They are widely available pharmaceutical excipients, so supply risk is generally lower than for specialized excipients. The greater risks are sterile fill-finish capacity, polysorbate quality, vial components, and validated lyophilization capacity.

Can Rezzayo support outpatient parenteral antifungal therapy?

Potentially. Weekly dosing improves logistical feasibility, but outpatient use still requires IV access, aseptic preparation, infusion monitoring, and management of safety risks. A ready-to-use presentation would strengthen the outpatient commercial case.

References

1. U.S. Food and Drug Administration. (2023). Rezzayo (rezafungin for injection) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
4. U.S. Food and Drug Administration. (2023, March 22). FDA approves new treatment for candidemia and invasive candidiasis.